Tolerability and immunogenicity of an intranasally-administered ...
Intranasal vaccination may induce protective local and systemic immune responses against respiratory pathogens. A number of intranasal SARS-CoV-2 vaccine candidates have achieved protection in pre-clinical challenge models, including ChAdOx1 nCoV-19 (AZD1222, University of Oxford / AstraZeneca).
Trying to Block SARS-CoV-2 Transmission With Intranasal Vaccines
Another recent study led by Munster suggested that an intranasal vaccine could effectively induce both types of immunity. He and his coauthors compared intranasal with intramuscular delivery of the Oxford/AstraZeneca vaccine.
Short-term effectiveness of single-dose intranasal spray COVID …
Sep 29, 2023 · When administered as a booster to individuals with a history of inactivated COVID-19 vaccination, a single-dose of dNS1-RBD provides protection against infections requiring medical attention at least in the short-term after vaccination.
Trial set to start of AstraZeneca Covid vaccine as nasal spray
Mar 25, 2021 · Oxford university has begun advertising for participants in an early-stage trial to deliver the Covid-19 vaccine it jointly developed with AstraZeneca as a nasal spray, according to documents...
Intranasal SARS-CoV-2 vaccination - Science | AAAS
Jul 27, 2021 · Intranasal vaccination with ChAdOx1 nCoV-19/AZD1222 reduced virus concentrations in nasal swabs in two different SARS-CoV-2 animal models, warranting further investigation as a potential vaccination route for COVID-19 vaccines.
Nasal Vaccines Are Here - The Atlantic
Dec 21, 2022 · After an intranasal version of the AstraZeneca vaccine roused great defenses in animals, a team at Oxford moved the immunization into a small human trial—and last month, published results...
Intranasal COVID-19 vaccines: From bench to bed - eBioMedicine …
Intranasal vaccination with mannosylated chitosan formulated DNA vaccine enables robust IgA and cellular response induction in the lungs of mice and improves protection against pulmonary mycobacterial challenge
The Oxford/AstraZeneca (ChAdOx1-S [recombinant] vaccine) …
Jun 13, 2022 · The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued interim recommendations for use of the Oxford/AstraZeneca COVID-19 vaccine (ChAdOx1-S [recombinant] vaccine). You may access the guidance document here.
Intranasal vaccines for SARS-CoV-2: From challenges to potential in ...
Nov 1, 2021 · mRNA vaccines developed by Pfizer/BioNTech and Moderna are available in the USA, UK, and elsewhere. Oxford/AstraZeneca AZD1222 (Covishield in India), JNJ-78436735 (Janssen Pharmaceutical, USA) and Gamaleya Sputnik V (Russia) are three adenoviral vector vaccines that have also been approved.
How nasal-spray vaccines could change the pandemic - Nature
Sep 6, 2022 · An intranasal vaccine from the firm Codagenix, in Farmingdale, New York, is administered as drops up the nose. It is in clinical trials. Credit: Serum Institute of India